Penumbra, Inc. (PEN) — ESG & Values Scores

Environment story

Penumbra disclosed no comprehensive Scope 1, 2, or 3 emissions data in the 10-K filing reviewed. No net-zero target year is disclosed. The company's sterilization process uses ethylene oxide at third-party facilities, which poses regulatory and supply-chain risks; EPA has proposed regulations to reduce hazardous emissions. No verified investments in physical decarbonization infrastructure are documented in the filing. The absence of material environmental disclosures and targets results in a moderate environmental score reflecting disclosed risks rather than robust climate commitments.

Criticisms on file

Ethylene Oxide Sterilization Dependency: Products are sterilized at third-party facilities using ethylene oxide. EPA has proposed regulations to reduce hazardous air pollutants from ethylene oxide emissions, and state agencies have mandated temporary closures of sterilization facilities. These regulatory and supply-chain risks could impact product sterilization timelines and costs.
Source: SEC 10-K, Item 1A Risk Factors, Section on 'Our dependence on third-party suppliers puts us at risk of interruptions in the availability of our products'; EPA environmental regulation references.

Disclosed initiatives

Manufacturing Facility Expansion

Penumbra is expanding facilities in Alameda, Roseville, California and constructing a new manufacturing facility in Costa Rica. The company notes these expansions are driven by growth in product manufacturing, development, and testing capacities.
Sterilization Process Review

Company acknowledges risks from EPA proposals to reduce ethylene oxide emissions at sterilization facilities and notes it is working to improve sterilization capacity and flexibility.

Ongoing mitigation of supply-chain sterilization risks; no net emissions reduction disclosed.

Social story

Penumbra does not disclose CEO-to-median-worker pay ratio, workforce turnover rate, or detailed diversity metrics (gender/race breakdown) in the 10-K. The company references workforce expansion and recruitment challenges, particularly in the competitive San Francisco Bay Area labor market, but does not provide union status, labor disputes, or supply-chain ethics data. The absence of comprehensive social disclosures limits transparency; no documented union-suppression activities, major strikes, or significant supply-chain human-rights controversies are mentioned in the filing.

Criticisms on file

Labor Market Concentration Risk: Penumbra's corporate headquarters, R&D, and primary manufacturing are located in the San Francisco Bay Area, a region with intense competition for qualified personnel and high cost of living. The company acknowledges risk of inability to attract and retain key personnel, which could harm product development and sales.
Source: SEC 10-K, Item 1A Risk Factors, Section on 'We depend on key personnel to operate our business and develop our products'.
Foreign Corruption Risk: Company operates in jurisdictions with experienced governmental corruption and works with distributors in Russia and a local partner in China. Company acknowledges that strict FCPA compliance may be at variance with local customs and practices, and that internal controls may not protect against reckless or criminal acts by employees, distributors, or agents.
Source: SEC 10-K, Item 1A Risk Factors, Section on 'Most of our customer relationships outside of the United States are with governmental entities'.

Disclosed initiatives

Workforce Expansion and Retention

Company emphasizes the need to attract and retain highly skilled research and development, sales, and technical personnel. Acknowledges competition for talent in the San Francisco Bay Area and high cost of living as challenges.

Company recognizes recruitment and retention as critical to business success but does not disclose formal retention programs or turnover metrics.
Employee Training and Education

Significant investment in training and education of sales representatives and specialist physicians to support product adoption and market acceptance.

Supports product adoption; no direct social welfare impact disclosed.
International Operations and Compliance

Company operates in multiple jurisdictions and has policies mandating compliance with FCPA, UK Bribery Act, and similar anti-bribery laws to prevent corruption in overseas operations.

Compliance framework established; no violations or enforcement actions disclosed in the filing.

Governance story

Penumbra does not disclose board independence percentage, share structure details, or annual lobbying expenditures in the 10-K filing reviewed. The company is subject to a pending acquisition by Boston Scientific (announced January 14, 2026 at $374 per share, 73% cash / 27% stock consideration), which introduces significant merger-related governance uncertainties and restrictions on business conduct. No active antitrust, consumer-safety, or financial-fraud regulatory proceedings are disclosed. No evidence of dual-class share structures, board independence below 75%, or systematic anti-environmental lobbying is documented in the filing. The absence of detailed governance metrics and the pending acquisition cloud impact assessment.

Criticisms on file

Pending Acquisition and Governance Uncertainty: On January 14, 2026, Penumbra agreed to be acquired by Boston Scientific Corporation for $374 per share. The merger subjects the company to restrictions on business conduct, including limits on entering into material contracts, acquiring/disposing assets outside ordinary course, and incurring indebtedness. Merger agreement includes a $525.0 million termination fee and provisions prohibiting alternative takeover proposals. Company faces risks of regulatory approval delays, antitrust challenges, and litigation. If merger fails, company may face significant financial penalty and stock price decline.
Source: SEC 10-K, Item 1A Risk Factors, Section on 'Risks Related to Our Proposed Merger'.
Regulatory Inspection and Corrective Actions: Company states it has previously received notices of inspectional observations or deficiencies from FDA and may receive such notices in the future. Compliance failures could result in fines, delays in regulatory approvals, seizures, recalls, or operating restrictions.
Source: SEC 10-K, Item 1A Risk Factors, Regulatory Risks Section.
Securities Litigation Risk: Company notes that product liability claims or recalls may trigger securities class action litigation. Company was involved in one such lawsuit in 2021, which was voluntarily dismissed without prejudice.
Source: SEC 10-K, Item 1A Risk Factors, Section on 'Defects or failures or alleged defects or failures associated with our products'.

Disclosed initiatives

Regulatory Compliance Framework

Company maintains compliance with FDA QMSR, EU MDR, ISO 13485:2016, and MDSAP standards. Conducts periodic inspections and surveillance audits to ensure ongoing compliance with medical device regulations.

Supports product safety and regulatory standing; successfully completed most recent surveillance audits in 2025.
Anti-Bribery and FCPA Compliance

Company has policies mandating compliance with FCPA, UK Bribery Act, Chinese Anti-Unfair Competition Law, and similar anti-bribery laws. Conducts training and compliance programs.

Governance framework for international operations; no violations disclosed.
Information Technology Systems and ERP Implementation

Company completed implementation of new enterprise resource planning (ERP) software system in 2023 to modernize business and operational processes. Ongoing investment in information technology systems maintenance and upgrades.

Aims to improve operational efficiency and financial controls; implementation entailed business disruption risks.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Penumbra, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Penumbra, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)